Skip to main content
. 2021 May 10;2021:9935076. doi: 10.1155/2021/9935076

Figure 4.

Figure 4

The correlation of irAEs with overall survival (OS). (a) In total patients, the irAE group and non-irAE group. (b) In total patients, the irAE group and other patients group within 3 months. (c) In total patients, irAEs of the grade ≥2 group and irAEs of the grade 1 or non-irAE group. (d) In the irAE subgroup, irAEs of grades 1, 2, and ≥3. (e) In total patients, the hepatic AEs group and other patients group. (f) In total patients, the “single-site” irAE or non-irAEs group and “multi-site” irAE group. (g) In the irAE subgroup, the “single-site” irAE group and “multi-site” irAE group. (h) In patients with lung cancer, the irAE group and non-irAE groups.